GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

Direct targeting of mutant KRas is challenging and alternative approaches are needed. Here they show glycogen synthase kinase 3 (GSK3) to be required for the growth and survival of human mutant KRas-dependent tumors but dispensable for mutant KRas-independent tumors and show GSK3 inhibition to inhib...

Descrición completa

Detalles Bibliográficos

Principais autores:	Aslamuzzaman Kazi, Shengyan Xiang, Hua Yang, Daniel Delitto, José Trevino, Rays H. Y. Jiang, Muhammad Ayaz, Harshani R. Lawrence, Perry Kennedy, Saïd M. Sebti
Formato:	Artigo
Idioma:	Inglês
Publicado:	Nature Portfolio 2018-12-01
Series:	Nature Communications
Acceso en liña:	https://doi.org/10.1038/s41467-018-07644-6
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!